Omberacetam is the nonproprietary name proposed for Noopept (see p.68, www.who.int/medicines/publications/druginformation/innlists/PL117.pdf?ua=1). Strictly speaking it does not belong to the racetam class of compounds (as it is a peptide). However, given its similarity it is often compared and categorized adjacent to other racetams.
On a purely pragmatic basis, I suggest we consider migrating Noopept to the racetam section. The INN may supplant the brand name in future but it's more important we set a standard in terms of naming conventions.
Update: PubChem now refers to Noopept as Omberacetam [ https://pubchem.ncbi.nlm.nih.gov/compound/Noopept ] Please see above regarding INN and re-categorizing Noopept into the racetam family on a pragmatic basis. -- (unsigned) Mydriasis, 14 January - 13 October 2018
- @Mydriasis: Done. I'll rename the article as well to reflect this change. Thanks for keeping us up to date! --Clarity (talk) 20:58, 23 October 2018 (CEST)
- We still haven't get the drug class changed yet. While omberacetam is not technically a 2-pyrrolidone because the C=O bond just ain't there, it's developed to be an analogue for one, so I think it deserves a double class designation like "peptide; racetam analogue". --Artoria2e5 (talk) 08:46, 15 September 2022 (UTC)